<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: It has been demonstrated that the alteration of human leukocyte antigen (HLA) class I expression frequently occurs in <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumor</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Previous studies mainly focused on the expression of HLA-A in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells </plain></SENT>
<SENT sid="2" pm="."><plain>The expression of HLA-A in peripheral blood mononuclear cells (PBMC) was unknown </plain></SENT>
<SENT sid="3" pm="."><plain>To develop a non-invasive diagnostic method for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>), this work investigated the expression of HLA-A <z:chebi fb="2" ids="33699">mRNA</z:chebi> in PBMC in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: Real-time quantitative RT-PCR was used to study the expression of HLA-A <z:chebi fb="2" ids="33699">mRNA</z:chebi> in PBMC from 48 patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, 38 patients with benign colorectal lesions, 20 patients with <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo>, 20 patients with <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e> and 40 healthy individuals </plain></SENT>
<SENT sid="5" pm="."><plain>Protein chip was utilized to detect the levels of serum CEA, CA 19-9, and CA 242 in <z:hpo ids='HP_0000001'>all</z:hpo> the cases </plain></SENT>
<SENT sid="6" pm="."><plain>Overall results from the two methods were compared </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: The relative expression of HLA-A <z:chebi fb="2" ids="33699">mRNA</z:chebi> in PBMC was 1.11 ± 0.45 in healthy group, 0.81 ± 0.42 in benign colorectal lesion group, and 0.39 ± 0.34 in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> group, respectively </plain></SENT>
<SENT sid="8" pm="."><plain>The diagnostic sensitivity of HLA-A <z:chebi fb="2" ids="33699">mRNA</z:chebi>, CEA, CA19-9, and CA242 was 81%, 59%, 61%, and 63%, and their diagnostic specificity was 75%, 64%, 52%, and 67%, respectively </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: The expression of HLA-A <z:chebi fb="2" ids="33699">mRNA</z:chebi> in PBMC from <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> group was significantly lower than those in both benign group and healthy group (P &lt; 0.001) </plain></SENT>
<SENT sid="10" pm="."><plain>It could be potentially developed as a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> assistant marker in future </plain></SENT>
</text></document>